CA2369999A1 - Enzymatically activated polymeric drug conjugates - Google Patents
Enzymatically activated polymeric drug conjugates Download PDFInfo
- Publication number
- CA2369999A1 CA2369999A1 CA002369999A CA2369999A CA2369999A1 CA 2369999 A1 CA2369999 A1 CA 2369999A1 CA 002369999 A CA002369999 A CA 002369999A CA 2369999 A CA2369999 A CA 2369999A CA 2369999 A1 CA2369999 A1 CA 2369999A1
- Authority
- CA
- Canada
- Prior art keywords
- conjugate
- gly
- pro
- linker
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13140499P | 1999-04-28 | 1999-04-28 | |
| US60/131,404 | 1999-04-28 | ||
| US16309099P | 1999-11-02 | 1999-11-02 | |
| US60/163,090 | 1999-11-02 | ||
| PCT/US2000/011670 WO2000064486A2 (en) | 1999-04-28 | 2000-04-28 | Enzymatically activated polymeric drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2369999A1 true CA2369999A1 (en) | 2000-11-02 |
Family
ID=26829434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002369999A Abandoned CA2369999A1 (en) | 1999-04-28 | 2000-04-28 | Enzymatically activated polymeric drug conjugates |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1176985A2 (ja) |
| JP (1) | JP2002542304A (ja) |
| AU (1) | AU772074B2 (ja) |
| CA (1) | CA2369999A1 (ja) |
| WO (1) | WO2000064486A2 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053362A3 (en) * | 2006-06-30 | 2011-03-03 | Interface Biologics, Inc. | Bioresponsive polymers |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2370245A1 (en) | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
| US6613879B1 (en) | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
| US6541508B2 (en) | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
| US6380405B1 (en) * | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| DE10018617A1 (de) * | 2000-01-13 | 2001-10-31 | Joerg G Moser | Cyclodextrin-Dimere mit Peptid-Spacerstrukturen zur Entgiftung von pharmazeutischen Wirkstoffen hohen Nebenwirkungspotentials |
| CA2401873A1 (en) | 2000-03-15 | 2001-09-20 | Robert A. Copeland | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| KR100406739B1 (ko) * | 2000-04-15 | 2003-11-20 | 주식회사 코오롱 | 파클리탁셀 또는 이의 유도체의 잔기를 포함하는 수용성프로드럭 화합물, 그의 제조 방법 및 그를 포함하는 약제조성물 |
| PL366216A1 (en) | 2000-11-01 | 2005-01-24 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US6919307B2 (en) | 2000-11-01 | 2005-07-19 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US7105482B2 (en) | 2000-11-01 | 2006-09-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| JP4290352B2 (ja) * | 2001-05-17 | 2009-07-01 | 独立行政法人科学技術振興機構 | 細胞シグナル応答型遺伝子転写制御系 |
| JP4840837B2 (ja) * | 2001-09-28 | 2011-12-21 | 日本たばこ産業株式会社 | 旨味を有する新規ペプチド、及びそれを旨味成分とする調味料 |
| GR20020100189A (el) * | 2002-04-17 | 2003-12-22 | Zeincro Ελλας Ανωνυμη Εταιρεια Συμβουλων Φαρμακευτικων Επιχειρησεων | Προφαρμακα αντιγονων ειδικων της προστατικης μεμβρανης |
| DE602004015589D1 (de) | 2003-04-28 | 2008-09-18 | Johnson & Johnson Medical Ltd | Schmerz-empfindliche therapeutische wundverbände |
| GB2402677A (en) * | 2003-05-06 | 2004-12-15 | Sirus Pharmaceuticals Ltd | Biodegradable polymer |
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| KR101200729B1 (ko) | 2003-09-17 | 2012-11-13 | 넥타르 테라퓨틱스 | 다분지형 고분자 전구약물 |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| KR101234476B1 (ko) | 2004-03-05 | 2013-02-18 | 덴끼 가가꾸 고교 가부시키가이샤 | 히알루론산/메토트렉세이트 화합물 |
| CN1956994B (zh) | 2004-03-31 | 2012-09-05 | 特许技术开发株式会社 | 上皮系细胞增殖促进剂 |
| TW200536861A (en) * | 2004-04-02 | 2005-11-16 | Denki Kagaku Kogyo Kk | Hyaluronic acid/methotrexate compound |
| ES2687786T3 (es) | 2004-04-21 | 2018-10-29 | Alexion Pharmaceuticals, Inc. | Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| EP1809291A4 (en) * | 2004-11-03 | 2012-04-04 | Forhumantech Co Ltd | PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL LEVY |
| DE102005007468A1 (de) * | 2005-02-16 | 2006-08-31 | Beiersdorf Ag | Kovalent gebundene Wirkkomplexe, aus denen Stress-aktivierbare Hautenzyme einen Wirkstoff freisetzen |
| US7671067B2 (en) | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| WO2008066902A2 (en) | 2006-11-30 | 2008-06-05 | Nektar Therapeutics Al, Corporation | Method for preparing a polymer conjugate |
| BRPI0807232A2 (pt) | 2007-02-09 | 2014-04-29 | Enzon Pharmaceuticals Inc | Tratamento de cânceres resistentes ou refratários com conjugados poliméricos multi-braços de 7-etil-10-hidroxicamptotecina |
| WO2009140683A1 (en) * | 2008-05-16 | 2009-11-19 | Research Foundation Of The City University Of New York | Living copolymer protein/peptide hybrids for biomedical applications |
| MX2011001583A (es) | 2008-08-11 | 2011-04-04 | Nektar Therapeutics | Conjugados de alcanoato polimericos de multiples brazos. |
| CA2736939C (en) | 2008-09-23 | 2021-09-14 | Nektar Therapeutics | Means of achieving sustained-therapeutic sn-38 concentrations in a subject |
| JP5986986B2 (ja) | 2010-04-30 | 2016-09-06 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 基質石灰化障害を治療する方法、組成物、およびキット |
| WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| EP2658979B1 (en) | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
| KR101972303B1 (ko) | 2011-06-10 | 2019-04-25 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-중합체-약물 접합체 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9907812B2 (en) * | 2011-06-22 | 2018-03-06 | Vyome Biosciences Pvt. Ltd. | Conjugate-based antifungal and antibacterial prodrugs |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| NL2010040C2 (en) * | 2012-12-21 | 2014-06-24 | Internat Inst For Diagnostic And Analitical Affairs B V | Cleavable coating material having microbial functionality. |
| MX367851B (es) | 2013-10-11 | 2019-09-09 | Mersana Therapeutics Inc | Conjugados de proteína-polímero-fármaco. |
| ES2754397T3 (es) | 2013-10-11 | 2020-04-17 | Asana Biosciences Llc | Conjugados de proteína-polímero-fármaco |
| US10653709B2 (en) | 2014-05-19 | 2020-05-19 | North Carolina State University | Methods of folding a graft copolymer with dual anticancer drugs and related applications |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| JP6516235B2 (ja) * | 2014-10-31 | 2019-05-22 | 国立大学法人富山大学 | キメラタンパク質及びそれを用いたミクログリア活性阻害剤 |
| US10449236B2 (en) | 2014-12-05 | 2019-10-22 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| RU2745528C2 (ru) | 2015-08-17 | 2021-03-26 | Алексион Фармасьютикалз, Инк. | Производство щелочных фосфатаз |
| WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
| EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| KR20220162816A (ko) | 2016-04-01 | 2022-12-08 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타아제로 근육 약화의 치료 |
| EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
| WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
| JP7018933B2 (ja) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 気管気管支軟化症の治療方法 |
| EP3555280A4 (en) | 2016-12-19 | 2020-09-09 | The Regents of The University of California | DUAL ENZYME-RESPONDING PEPTIDES |
| US11541125B2 (en) | 2016-12-19 | 2023-01-03 | The Regents Of The University Of California | Noncrushable pill formulations |
| MX2019011508A (es) | 2017-03-31 | 2019-11-01 | Alexion Pharma Inc | Metodos para tratar la hipofosfatasia (hpp) en adultos y adolescentes. |
| KR102095284B1 (ko) * | 2017-05-11 | 2020-04-01 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06506217A (ja) * | 1991-03-18 | 1994-07-14 | エンゾン，インコーポレーテッド | ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体 |
| US5658592A (en) * | 1994-05-13 | 1997-08-19 | Kuraray Co., Ltd. | Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane |
| US5980883A (en) * | 1996-10-02 | 1999-11-09 | Kuraray Co., Ltd. | Polymer gel for medical use |
| WO1998019705A1 (en) * | 1996-11-05 | 1998-05-14 | Bristol-Myers Squibb Company | Branched peptide linkers |
| EP1146860A4 (en) * | 1999-01-08 | 2002-07-03 | Emisphere Tech Inc | POLYMER DRUG DELIVERY SYSTEMS AND COMPOUNDS |
-
2000
- 2000-04-28 EP EP00928630A patent/EP1176985A2/en not_active Withdrawn
- 2000-04-28 CA CA002369999A patent/CA2369999A1/en not_active Abandoned
- 2000-04-28 JP JP2000613476A patent/JP2002542304A/ja active Pending
- 2000-04-28 AU AU46835/00A patent/AU772074B2/en not_active Ceased
- 2000-04-28 WO PCT/US2000/011670 patent/WO2000064486A2/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053362A3 (en) * | 2006-06-30 | 2011-03-03 | Interface Biologics, Inc. | Bioresponsive polymers |
| US8962697B2 (en) | 2006-06-30 | 2015-02-24 | Interface Biologics Inc. | Bioreponsive polymers |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002542304A (ja) | 2002-12-10 |
| EP1176985A2 (en) | 2002-02-06 |
| WO2000064486A2 (en) | 2000-11-02 |
| WO2000064486A3 (en) | 2001-04-26 |
| AU4683500A (en) | 2000-11-10 |
| AU772074B2 (en) | 2004-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU772074B2 (en) | Enzymatically activated polymeric drug conjugates | |
| US20040228831A1 (en) | Polymeric conjugates for tissue activated drug delivery | |
| CN102516417B (zh) | 用于传递治疗剂的以环糊精为基础的聚合物 | |
| CN100522249C (zh) | 可活化的药物前体中的加长的多间隔基 | |
| AU2002345981B2 (en) | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers | |
| US8703116B2 (en) | Modified macromolecule | |
| ES2371865T3 (es) | Conjugados de hidroxialquilalmidón-principio activo. | |
| CN101218280B (zh) | 胞苷代谢拮抗剂的聚合衍生物 | |
| AU679788B2 (en) | Polymer-bound camptothecin derivatives | |
| CN100475269C (zh) | 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途 | |
| GB2427360A (en) | Aliphatic prodrug linker | |
| JPWO2006115293A1 (ja) | ｐＨ応答性高分子ミセルの調製に用いる新規ブロック共重合体及びその製造法 | |
| KR20020010363A (ko) | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 | |
| CN102139114A (zh) | 聚合物-因子viii部分缀合物 | |
| US20040087483A1 (en) | Iodothyronine compositions | |
| CN1694728B (zh) | 用于传递治疗剂的以环糊精为基础的聚合物 | |
| JP2004504358A (ja) | 抗腫瘍薬のポリマー複合体 | |
| JP5105166B2 (ja) | ポリエーテルの製造方法 | |
| KR100562895B1 (ko) | 약물의 간세포 표적화를 위한 생물학적 활성 고분자 결합체 | |
| JP5189243B2 (ja) | 薬物複合体および薬物送達用担体 | |
| EP1357928B1 (en) | A novel pharmaceutical compound and methods of making and using same | |
| EP1401374B1 (en) | A novel pharmaceutical compound containing atenolol and methods of making and using same | |
| WO2003072047A2 (en) | Idothyronine compositions | |
| Floyd III | Synthesis and Evaluation of Dendritic Polymer Carriers for Chemotherapeutic and Imaging Applications | |
| KR20030039541A (ko) | 표적지향형 항암특성을 가지는 암세포 특이 전달자 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDC | Correction of dead application (reinstatement) | ||
| EEER | Examination request | ||
| FZDE | Dead |